文献速递肺栓塞与肺血管病

肺高血压的定义、分类与诊断

Definition, classification and diagnosis of pulmonary hypertension.
PubMed 文献 · Eur Respir J · 2024-10-31

本文阐述肺高血压(PH)的血流动力学定义:右心导管测得平均肺动脉压(mPAP)>20 mmHg。通过肺动脉楔压(PAWP)和肺血管阻力(PVR)区分毛细血管前、单纯毛细血管后及混合性PH。临床分类保留五大类,并有多项更新;诊断推荐阶梯式流程,以识别需转诊至PH中心并接受有创血流动力学评估的患者。

要点

  • PH定义为右心导管测得mPAP>20 mmHg。
  • 毛细血管前PH:PAWP≤15 mmHg且PVR>2 WU。
  • 高概率严重肺血管病或右心衰征象时建议快速转诊PH中心。

核心结论

  • PH是右心导管测得mPAP>20 mmHg的血流动力学状态。
  • 临床分类保留五大类,但部分亚组有调整。
  • 诊断采用阶梯式流程,旨在识别需转诊PH中心及有创评估的患者。

研究设计与样本

  • 本文为欧洲呼吸学会(Eur Respir J)发布的肺高血压定义、分类与诊断的综述/立场文件。

主要发现

  • 毛细血管前PH:PAWP≤15 mmHg且PVR>2 WU。
  • 单纯毛细血管后PH:PAWP>15 mmHg且PVR≤2 WU。
  • 混合性毛细血管后和毛细血管前PH:PAWP>15 mmHg且PVR>2 WU。
  • 运动性PH定义为静息mPAP正常,运动时mPAP/心输出量斜率>3 mmHg/L/min。
  • 临床分类保留五大类,但重新引入「钙通道阻滞剂长期应答者」作为特发性肺动脉高压亚组,第2类PH增加亚组,第3类PH亚组基于肺疾病而非功能异常区分。

关键数值与推荐

  • PH:mPAP>20 mmHg(右心导管)。
  • 毛细血管前PH:PAWP≤15 mmHg且PVR>2 WU。
  • 单纯毛细血管后PH:PAWP>15 mmHg且PVR≤2 WU。
  • 混合性PH:PAWP>15 mmHg且PVR>2 WU。
  • 运动性PH:静息mPAP正常,运动时mPAP/心输出量斜率>3 mmHg/L/min。

临床怎么用

  • 采用阶梯式诊断流程,识别需转诊PH中心及有创血流动力学评估的患者。
  • 高概率严重肺血管病,尤其有右心衰征象时,任何阶段均建议快速转诊PH中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of mean pulmonary arterial pressure (mPAP) >20 mmHg, assessed by right heart catheterisation. Pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) distinguish pre-capillary PH (PAWP ≤15 mmHg, PVR >2 Wood Units (WU)), isolated post-capillary PH (PAWP >15 mmHg, PVR ≤2 WU) and combined post- and pre-capillary PH (PAWP >15 mmHg, PVR >2 WU). Exercise PH is a haemodynamic condition describing a normal mPAP at rest with an abnormal increase of mPAP during exercise, defined as a mPAP/cardiac output slope >3 mmHg/L/min between rest and exercise. The core structure of the clinical classification of PH has been retained, including the five major groups. However, some changes are presented herewith, such as the re-introduction of "long-term responders to calcium channel blockers" as a subgroup of idiopathic pulmonary arterial hypertension, the addition of subgroups in group 2 PH and the differentiation of group 3 PH subgroups based on pulmonary diseases instead of functional abnormalities. Mitomycin-C and carfilzomib have been added to the list of drugs with "definite association" with PAH. For diagnosis of PH, we propose a stepwise approach with the main aim of discerning those patients who need to be referred to a PH centre and who should undergo invasive haemodynamic assessment. In case of high probability of severe pulmonary vascular disease, especially if there are signs of right heart failure, a fast-track referral to a PH centre is recommended at any point during the clinical workup.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Kovacs G, Bartolome S, Denton CP, et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024. PMID: 39209475. doi:10.1183/13993003.01324-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。